Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 2, 1996, Pages 607-611

  Nakayama, Konosuke ^a   Fukumoto, Seiji ^a   Takeda, Shu ^a   Takeuchi, Yasuhiro ^a   Ishikawa, Toshio ^a   Miura, Masakazu ^b   Hata, Keishi ^b   Hane, Motomu ^c   Tamura, Yoshinori ^c   Tanaka, Yoh ^d   Kitaoka, Masafumi ^e   Obara, Takao ^f   Ogata, Etsuro ^g   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Mitsubishi Kagaku Bio Clin Labs   (Japan)

^c MITSUBISHI CHEMICAL CORPORATION   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^e Showa General Hospital   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE METABOLISM; CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERCALCEMIA; MALE; OSTEOLYSIS; PARATHYROID HORMONE RELEASE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; VITAMIN D METABOLISM;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; BONE AND BONES; BONE RESORPTION; CALCITRIOL; CALCIUM; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; NEOPLASMS; OSTEOCALCIN; VITAMIN D;

EID: 9044246269     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.2.607     Document Type: Article

References (33)

1. Broadus AE, Mangin M, Ikeda K, et al. 1988 Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. [Review]. New Engl J Med. 319:556-563.
2. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. 1980 Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. New Eng J Med. 303:1377-1383.
3. Suva LJ, Winslow GA, Wettenhall RE, et al. 1987 A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science (Wash DC). 237:893-896.
4. Mangin M, Webb AC, Dreyer BE, et al. 1988 Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA. 85:597-601.
5. Juppner H, Abou-Samra AB, Freeman M, et al. 1991 A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science (Wash DC) 254:1024-1026.
6. Horiuchi N, Caulfield MP, Fisher JE, et al. 1987 Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science (Wash DC) 238:1566-1568.
7. Kemp BE, Moseley JM, Rodda CP, et al. 1987 Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science (Wash DC) 238: 1568-1570.
8. Stewart AF, Vignery A, Silverglate A, et al. 1982 Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab. 55:219-227.
9. McDonnell GD, Dunstan CR, Evans RA, et al. 1982 Quantitative bone histology in the hypercalcemia of malignant disease. J Clin Endocrinol Metab. 55:1066-1072.
10. 3 production. Endocrinology. 124:2057-2062.
11. Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F. 1993 Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab. 76:801-803.
12. Payne RB, Little AJ, Williams RB, Milner JR. 1973 Interpretation of serum calcium in patients with abnormal serum proteins. Brit Med J. 4:643-646.
13. Ikeda K, Ohno H, Hane M, et al. 1994 Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/ lymphoma and B-cell lymphoma. J Clin Endocrinol Metab. 79:1322-1327.
14. Kawaguchi H, Matsumoto T, Kurokawa T, et al. 1990 Serum levels of BGP determined by two-site immunoradiometric assay (IRMA) using monoclonal antibodies. Horumon to Rinsho (in Japanese). 38:1291-1296.
15. Garnero P, Grimaux M, Seguin P, Delmas PD. 1994 Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 9:255-264.
16. Hata K, Tokuhiro H, Miura M. 1994 Precision assay of bone-type alkaline phosphatase. Jpn J Clin Chem (in Japanese). 23:26-31.
17. Melkko J, Niemi S, Risteli L, Risteli J. 1990 Radioimmunoassay of the carboxyterminal propeptide of human type 1 procollagen. Clin Chem. 36:1328-1332.
18. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 39:635-640.
19. Hata K, Miura M, Fukumoto S, Matsumoto T. 1995 Assay of serum pyridinoline: a potential marker for bone resorption. Clin Chim Acta. 235:221-227.
20. Seyedin SM, Kung VT, Daniloff YN, et al. 1993 Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res. 8:635-641.
21. Hollis BW. 1986 Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure. Clin Chem. 32: 2060-2063.
22. Wallenstein S, Zucker CL, Fleiss JL. 1980 Some statistical methods useful in circulation research. Circ Res. 47:1-9.
23. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. 1995 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res. 10:641-649.
24. Garnero P, Shin WJ, Gineyts E, Karpf DB, Delmas PD. 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1693-1700.
25. Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R, Mundy GR. 1991 Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest. 87:977-985.
26. Sato K, Fujii Y, Kasono K, Tsushima T, Shizume K. 1988 Production of interleukin-1 alpha and a parathyroid hormone-like factor by a squamous cell carcinoma of the esophagus (EC-GI) derived from a patient with hypercalcemia. J Clin Endocrinol Metab. 67:592-601.
27. Sato K, Fujii Y, Kasono K, et al. 1989 Parathyroid hormone-related protein and interleukin-1 alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology. 124: 2172-2178.
28. Johnson RA, Boyce BF, Mundy GR, Roodman GD. 1989 Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology. 124:1424-1427.
29. Yoneda T, Nakai M, Moriyama K, et al. 1993 Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res. 53:737-740.
30. Hughes FJ, Howells GL. 1993 Interleukin-6 inhibits bone formation in vitro. Bone Miner. 21:21-28.
31. Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD. 1987 Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J Bone Miner Res. 2:559-565.
32. Canalis E. 1987 Effects of tumor necrosis factor on bone formation in vitro. Endocrinology. 121:1596-1604.
33. Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P. 1991 Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res. 10:15-21.